Johnson & Johnson (0R34) Share Forecast & Price Target

62 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0R34 Analyst Ratings

Moderate Buy

12 Buy

6 Hold

0 Sell

Based on 18 analysts giving stock ratings to

Johnson

& Johnson

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0R34 Stock 12 Month Forecast

Average Price Target

$288.71

▲(7.83% Upside)

Based on 18 Wall Street analysts offering 12 month price targets for Johnson & Johnson in the last 3 months. The average price target is $288.71 with a high forecast of $320.00 and a low forecast of $260.00. The average price target represents a 7.83% change from the last price of $267.74.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"180":"$180","321":"$321","215.25":"$215.3","250.5":"$250.5","285.75":"$285.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":320,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$320.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":288.70588235294116,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$288.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":260,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$260.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[180,215.25,250.5,285.75,321],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,259.4,264.0615384615384,268.7230769230769,273.38461538461536,278.04615384615386,282.7076923076923,287.36923076923074,292.03076923076924,296.6923076923077,301.3538461538461,306.0153846153846,310.67692307692306,315.33846153846156,{"y":320,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,259.4,261.6542986425339,263.90859728506786,266.16289592760177,268.41719457013573,270.67149321266965,272.9257918552036,275.1800904977375,277.4343891402715,279.6886877828054,281.94298642533937,284.1972850678733,286.45158371040725,{"y":288.70588235294116,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,259.4,259.44615384615383,259.4923076923077,259.53846153846155,259.58461538461535,259.6307692307692,259.67692307692306,259.7230769230769,259.7692307692308,259.81538461538463,259.86153846153843,259.9076923076923,259.95384615384614,{"y":260,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":181.756,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":184.787,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":203.208,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":204,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":225.914,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":244.844,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":241.777,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":225.682,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":222.107,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":251.81,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":256.934,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":269.98,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":259.4,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$320.00

Average Price Target$288.71

Lowest Price Target$260.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Hans Engel

Erste Group

―

Hold

―

Downgraded

10/21/26

Johnson & Johnson downgraded to Hold from Buy at Erste GroupJohnson & Johnson downgraded to Hold from Buy at Erste Group

Chris LoBianco

TD Cowen

Not Ranked

TD Cowen

$300

Buy

12.05%

Upside

Assigned

10/19/26

Johnson & Johnson: Buy Rating Reiterated on Underappreciated Pharma and MedTech Growth, $300 Price Target Unchanged

David Risinger

Leerink Partners

$276→$272

Buy

1.59%

Upside

Reiterated

10/15/26

Johnson & Johnson (JNJ) Receives a Rating Update from a Top Analyst

Terence Flynn

Morgan Stanley

$294→$292

Buy

9.06%

Upside

Reiterated

10/15/26

J&J Buy Rating Reiterated as Long-Term Pipeline Strength Supports Outlook; $294 Price Target Unchanged

Larry Biegelsen

Wells Fargo

$275→$287

Buy

7.19%

Upside

Reiterated

10/15/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Johnson & Johnson (NYSE: JNJ) and Liquidia Technologies (NASDAQ: LQDA)

Jason Gerberry

Bank of America Securities

$275

Hold

2.71%

Upside

Reiterated

10/14/26

Analysts Conflicted on These Healthcare Names: UnitedHealth (NYSE: UNH), BrightSpring Health Services, Inc. (NASDAQ: BTSG) and Johnson & Johnson (NYSE: JNJ)

Louise Chen

Scotiabank

$305

Buy

13.92%

Upside

Reiterated

10/14/26

Analysts Are Bullish on These Healthcare Stocks: Omeros (OMER), Johnson & Johnson (JNJ)

Lee Hambright

Bernstein

$261→$270

Hold

0.84%

Upside

Reiterated

10/14/26

Analysts Offer Insights on Healthcare Companies: UnitedHealth (NYSE: UNH), United Therapeutics (NASDAQ: UTHR) and Johnson & Johnson (NYSE: JNJ)

Trung Huynh

RBC Capital

$290→$280

Buy

4.58%

Upside

Reiterated

10/13/26

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (NYSE: JNJ), Revolution Medicines (NASDAQ: RVMD) and Viridian Therapeutics (NASDAQ: VRDN)

Rick Wise

Stifel Nicolaus

$260

Hold

-2.89%

Downside

Reiterated

10/12/26

Stifel Nicolaus Reaffirms Their Hold Rating on Johnson & Johnson (JNJ)

Michael Yee

UBS

$320

Buy

19.52%

Upside

Reiterated

10/09/26

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (NYSE: JNJ), United Therapeutics (NASDAQ: UTHR) and Ionis Pharmaceuticals (NASDAQ: IONS)

Vamil Divan

Guggenheim

$287

Buy

7.19%

Upside

Reiterated

10/06/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Aclaris Therapeutics (NASDAQ: ACRS), Globus Medical (NYSE: GMED) and Johnson & Johnson (NYSE: JNJ)

Joanne Wuensch

Citi

$298→$303

Buy

13.17%

Upside

Reiterated

10/05/26

Johnson & Johnson price target raised to $303 from $298 at CitiJohnson & Johnson price target raised to $303 from $298 at Citi

Chris Schott

J.P. Morgan

$270→$285

Hold

6.45%

Upside

Reiterated

09/29/26

Johnson & Johnson price target raised to $285 from $270 at JPMorganJohnson & Johnson price target raised to $285 from $270 at JPMorgan

Nico Chen

DBS

$270

Hold

0.84%

Upside

Reiterated

09/11/26

DBS Sticks to Their Hold Rating for Johnson & Johnson (JNJ)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Hans Engel

Erste Group

―

Hold

―

Downgraded

10/21/26

Johnson & Johnson downgraded to Hold from Buy at Erste GroupJohnson & Johnson downgraded to Hold from Buy at Erste Group

Chris LoBianco

TD Cowen

Not Ranked

TD Cowen

$300

Buy

12.05%

Upside

Assigned

10/19/26

Johnson & Johnson: Buy Rating Reiterated on Underappreciated Pharma and MedTech Growth, $300 Price Target Unchanged

David Risinger

Leerink Partners

$276→$272

Buy

1.59%

Upside

Reiterated

10/15/26

Johnson & Johnson (JNJ) Receives a Rating Update from a Top Analyst

Terence Flynn

Morgan Stanley

$294→$292

Buy

9.06%

Upside

Reiterated

10/15/26

J&J Buy Rating Reiterated as Long-Term Pipeline Strength Supports Outlook; $294 Price Target Unchanged

Larry Biegelsen

Wells Fargo

$275→$287

Buy

7.19%

Upside

Reiterated

10/15/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Johnson & Johnson (NYSE: JNJ) and Liquidia Technologies (NASDAQ: LQDA)

Jason Gerberry

Bank of America Securities

$275

Hold

2.71%

Upside

Reiterated

10/14/26

Analysts Conflicted on These Healthcare Names: UnitedHealth (NYSE: UNH), BrightSpring Health Services, Inc. (NASDAQ: BTSG) and Johnson & Johnson (NYSE: JNJ)

Louise Chen

Scotiabank

$305

Buy

13.92%

Upside

Reiterated

10/14/26

Analysts Are Bullish on These Healthcare Stocks: Omeros (OMER), Johnson & Johnson (JNJ)

Lee Hambright

Bernstein

$261→$270

Hold

0.84%

Upside

Reiterated

10/14/26

Analysts Offer Insights on Healthcare Companies: UnitedHealth (NYSE: UNH), United Therapeutics (NASDAQ: UTHR) and Johnson & Johnson (NYSE: JNJ)

Trung Huynh

RBC Capital

$290→$280

Buy

4.58%

Upside

Reiterated

10/13/26

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (NYSE: JNJ), Revolution Medicines (NASDAQ: RVMD) and Viridian Therapeutics (NASDAQ: VRDN)

Rick Wise

Stifel Nicolaus

$260

Hold

-2.89%

Downside

Reiterated

10/12/26

Stifel Nicolaus Reaffirms Their Hold Rating on Johnson & Johnson (JNJ)

Michael Yee

UBS

$320

Buy

19.52%

Upside

Reiterated

10/09/26

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (NYSE: JNJ), United Therapeutics (NASDAQ: UTHR) and Ionis Pharmaceuticals (NASDAQ: IONS)

Vamil Divan

Guggenheim

$287

Buy

7.19%

Upside

Reiterated

10/06/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Aclaris Therapeutics (NASDAQ: ACRS), Globus Medical (NYSE: GMED) and Johnson & Johnson (NYSE: JNJ)

Joanne Wuensch

Citi

$298→$303

Buy

13.17%

Upside

Reiterated

10/05/26

Johnson & Johnson price target raised to $303 from $298 at CitiJohnson & Johnson price target raised to $303 from $298 at Citi

Chris Schott

J.P. Morgan

$270→$285

Hold

6.45%

Upside

Reiterated

09/29/26

Johnson & Johnson price target raised to $285 from $270 at JPMorganJohnson & Johnson price target raised to $285 from $270 at JPMorgan

Nico Chen

DBS

$270

Hold

0.84%

Upside

Reiterated

09/11/26

DBS Sticks to Their Hold Rating for Johnson & Johnson (JNJ)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

PTGXProtagonist Therapeutics

SIBNSI-Bone

IMUXImmunic

MDWDMediwound

HROWHarrow Health

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Johnson & Johnson

3 Months

Asad HaiderGoldman Sachs

Success Rate

12/15 ratings generated profit

Average Return

+9.50%

Copying Asad Haider's trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +9.50% per trade.

1 Year

Asad HaiderGoldman Sachs

Success Rate

15/15 ratings generated profit

Average Return

+31.94%

Copying Asad Haider's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +31.94% per trade.

2 Years

Asad HaiderGoldman Sachs

Success Rate

15/15 ratings generated profit

Average Return

+37.35%

Copying Asad Haider's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +37.35% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0R34 Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0R34 has received 32 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. 0R34 average Analyst price target in the past 3 months is 288.71.

Each month's total comprises the sum of three months' worth of ratings.

0R34 Financial Forecast

0R34 Earnings Forecast

Next quarter’s earnings estimate for 0R34 is $2.90 with a range of $2.74 to $2.96. The previous quarter’s EPS was $2.59. 0R34 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0R34 has Performed in-line its overall industry.

0R34 Sales Forecast

Next quarter’s sales forecast for 0R34 is $26.41B with a range of $26.23B to $26.68B. The previous quarter’s sales results were $25.40B. 0R34 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0R34 has Performed in-line its overall industry.

0R34 Stock Forecast FAQ

What is GB:0R34’s average 12-month price target, according to analysts?

Based on analyst ratings, Johnson & Johnson’s 12-month average price target is 288.71.

What is GB:0R34’s upside potential, based on the analysts’ average price target?

Johnson & Johnson has 7.83% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Johnson & Johnson a Buy, Sell or Hold?

Johnson & Johnson has a consensus rating of Moderate Buy, which is based on 12 buy ratings, 6 hold ratings and 0 sell ratings.

What is Johnson & Johnson’s share price target?

The average share price target for Johnson & Johnson is 288.71. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $320.00 ,and the lowest forecast is $260.00. The average share price target represents 7.83% Increase from the current price of $267.74.

What do analysts say about Johnson & Johnson?

Johnson & Johnson’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 18 Wall Streets Analysts.

How can I buy shares of Johnson & Johnson?

To buy shares of GB:0R34, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Johnson & Johnson (0R34) Share Forecast & Price Target

0R34 Analyst Ratings

0R34 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Johnson & Johnson

0R34 Analyst Recommendation Trends

0R34 Financial Forecast

0R34 Earnings Forecast

0R34 Sales Forecast

0R34 Stock Forecast FAQ

Detailed List of Analyst Forecasts